Silexion Therapeutics Corp 8-K

What Happened Silexion Therapeutics Corp (SLXN) announced that at an extraordinary general meeting originally held April 28, 2026 and reconvened May 5, 2026, shareholders approved an amendment to paragraph 5 of the company’s amended and restated memorandum of association to increase the company’s authorized share capital. The Memorandum Amendment was filed with the Registrar of Companies in the Cayman Islands and became effective on May 5, 2026. A copy of the Memorandum Amendment is attached to the 8-K as Exhibit 3.1.

Key Details

• Shareholder meeting: originally April 28, 2026; reconvened and concluded May 5, 2026.
• Action approved: amendment to paragraph 5 of the memorandum increasing authorized share capital.
• Effective date: memorandum amendment filed and effective May 5, 2026 with the Cayman Islands Registrar.
• Documentation: full Memorandum Amendment is attached as Exhibit 3.1 to the Form 8-K for specific terms.

Why It Matters Increasing authorized share capital gives the company legal capacity to issue more shares in the future for financing, acquisitions, or equity compensation. That can enable growth or fundraising but may also lead to dilution of existing shareholders if and when new shares are issued. Investors should review the attached Memorandum Amendment (Exhibit 3.1) for the exact change in authorized shares and monitor future filings for any share issuances or related financing plans.